Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | BCHE | P06276 | 5/20 | 0.58 |
| ▸ | BACE1 | P56817 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148010 | 1.00 | HRH3 (0.59) | HRH3ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL6182247 | 1.00 | HRH3 (0.59) | HRH3ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL7319631 | 0.89 | ACHE (0.62) | ACHEBCHEBACE1ALDH1A1SIGMAR1 | |
| SCHEMBL6503566 | 0.89 | FUCA1 (0.56) | HRH3ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL6503563 | 0.89 | FUCA1 (0.56) | HRH3ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL18477518 | 0.87 | FUCA1 (0.55) | HRH3ACHEBCHEBACE1CYP1A2 | |
| SCHEMBL15082004 | 0.85 | FUCA1 (0.56) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL500532 | 0.85 | FUCA1 (0.56) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL14157508 | 0.85 | FUCA1 (0.56) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL14157505 | 0.85 | FUCA1 (0.56) | ACHEBCHEBACE1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | HRH3 120/4885ACHE 270/4885BCHE 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.